YahooOctober 26, 2026 at 1:03 PM NYYesterday
Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial
Alnylam Pharmaceuticals (NASDAQ:ALNY) outlined early clinical data for brezosiran, an investigational RNA interference therapy for Huntington’s disease, reporting dose-dependent reductions in cerebrospinal fluid mutant huntingtin after a single intrathecal dose and plans to begin a placebo-controlle
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
